Inventor · disambiguated record
Chunguang Guo
Also filed as: GUO CHUNGUANG
7 granted patents·8 pending applications·5 citations·filing 2017–2025
75Inventor score
Files withREGENERON PHARMA15
Top patents by PatentIndex Score
15 records- 0188US10820582B2Non-human animals having an engineered immunoglobulin Λ light chain locusREGENERON PHARMA·Filed 2017·Granted Nov 3, 2020·3 cites·21 claims
- 0284US11051498B2Mouse having an engineered immunoglobulin lambda light chainREGENERON PHARMA·Filed 2018·Granted Jul 6, 2021·2 cites·14 claims
- 0373US2025302017A1Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrb repertoireREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 0473US2025386808A1Non-human animals expressing exogenous terminal deoxynucleotidyltransferaseREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 0571US12295354B2Non-human animals expressing exogenous terminal deoxynucleotidyltransferaseREGENERON PHARMA·Filed 2021·Granted May 13, 2025·0 cites·19 claims
- 0670US12376573B2Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoireREGENERON PHARMA·Filed 2022·Granted Aug 5, 2025·0 cites·23 claims
- 0770US12356967B2Immunoglobulin lambda light chain and uses thereofREGENERON PHARMA·Filed 2021·Granted Jul 15, 2025·0 cites·28 claims
- 0868US12433264B2Non-human animals having an engineered immunoglobulin lambda light chain locusREGENERON PHARMA·Filed 2020·Granted Oct 7, 2025·0 cites·21 claims
- 0965US2019380316A1Non-human animals capable of engineered dh-dh rearrangement and uses thereofREGENERON PHARMA·Filed 2019·Application pending·0 cites
- 1064US2024099279A1Genetically modified mice expressing components of human cellular immune systemREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1163US10980221B2Non-human animals expressing exogenous terminal deoxynucleotidyltransferaseREGENERON PHARMA·Filed 2017·Granted Apr 20, 2021·0 cites·21 claims
- 1261US2022090060A1Identification and production of antigen-specific antibodiesREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1360US2021251202A1Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequencesREGENERON PHARMA·Filed 2019·Application pending·0 cites
- 1460US2020370054A1Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locusREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 1550US2022330532A1Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereofREGENERON PHARMA·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Chunguang Guo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →